Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Awada

Showing results (51-60 of 311) with videos related to

Pageof 32
Sort By:
The New England Journal of Medicine|September 8, 2006
Molecular profiling of a tumor of unknown originGustavo Ismael, Evandro de Azambuja, Ahmad Awada
F1000Research|May 10, 2019
Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancerGeorges El Hachem, Andrea Gombos, Ahmad Awada
Cancer Treatment Reviews|February 7, 2012
New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?Ahmad Awada, Ivana Bozovic-Spasojevic, Louis Chow
Immunotherapy|June 28, 2017
The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectivesHampig Raphael Kourie, Gil Awada, Ahmad Awada
The Lancet. Oncology|January 4, 2006
Keynote comment: reimbursement for molecularly targeted anticancer agentsUmberto Tirelli, Gilberto de Castro, Ahmad Awada
Expert Opinion on Drug Metabolism & Toxicology|November 2, 2017
Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patientsGil Awada, Evandro de Azambuja, Ahmad Awada
The Oncologist|August 13, 2008
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumorsLissandra Dal Lago, Véronique D'Hondt, Ahmad Awada
Expert Opinion on Investigational Drugs|April 9, 2010
Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trendsOtto Metzger-Filho, Tushar Vora, Ahmad Awada
Critical Reviews in Oncology/Hematology|April 24, 2010
Febrile neutropenia: a critical review of the initial managementJean Klastersky, Ahmad Awada, Mariane Paesmans, et al.
Expert Opinion on Emerging Drugs|January 29, 2016
Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancerGil Awada, Andrea Gombos, Philippe Aftimos, et al.
Pageof 32

Showing results (51-60 of 311) with videos related to

Sort By:
Pageof 32
The New England Journal of Medicine|September 8, 2006
Molecular profiling of a tumor of unknown originGustavo Ismael, Evandro de Azambuja, Ahmad Awada
F1000Research|May 10, 2019
Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancerGeorges El Hachem, Andrea Gombos, Ahmad Awada
Cancer Treatment Reviews|February 7, 2012
New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?Ahmad Awada, Ivana Bozovic-Spasojevic, Louis Chow
Immunotherapy|June 28, 2017
The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectivesHampig Raphael Kourie, Gil Awada, Ahmad Awada
The Lancet. Oncology|January 4, 2006
Keynote comment: reimbursement for molecularly targeted anticancer agentsUmberto Tirelli, Gilberto de Castro, Ahmad Awada
Expert Opinion on Drug Metabolism & Toxicology|November 2, 2017
Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patientsGil Awada, Evandro de Azambuja, Ahmad Awada
The Oncologist|August 13, 2008
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumorsLissandra Dal Lago, Véronique D'Hondt, Ahmad Awada
Expert Opinion on Investigational Drugs|April 9, 2010
Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trendsOtto Metzger-Filho, Tushar Vora, Ahmad Awada
Critical Reviews in Oncology/Hematology|April 24, 2010
Febrile neutropenia: a critical review of the initial managementJean Klastersky, Ahmad Awada, Mariane Paesmans, et al.
Expert Opinion on Emerging Drugs|January 29, 2016
Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancerGil Awada, Andrea Gombos, Philippe Aftimos, et al.
Pageof 32